Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
作者： Giuseppe Giaccone , Roy S. Herbst , Christian Manegold , Giorgio Scagliotti , Rafael Rosell
关键词: Necitumumab 、 Gemcitabine 、 Gefitinib 、 Surgery 、 Multicenter trial 、 Oncology 、 Internal medicine 、 Lung cancer 、 Tolerability 、 Medicine 、 Chemotherapy 、 Cisplatin
摘要: … a high overall adherence to gefitinib; however, most gefitinib dose interruptions and reductions were seen in the gefitinib 500 mg/d arm (the number was similar in the gefitinib 250 mg/d …
elsevier.com
jco.org参考文章(17)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
A.B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, Ch. Manegold, M.C. Palmer, A. Gregor, B. Nguyen, C. Niyikiza, L.H. Einhorn, Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 18, pp. 122- 122 ,(2000) , 10.1200/JCO.2000.18.1.122
Stuart J. Pocock, Richard Simon, Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial Biometrics. ,vol. 31, pp. 103- 115 ,(1975) , 10.2307/2529712
J.R Woodburn, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics. ,vol. 82, pp. 241- 250 ,(1999) , 10.1016/S0163-7258(98)00045-X
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
Renee Bailey, Mark Kris, Michael Wolf, Andrea Kay, Steven Averbuch, Jon Askaa, Mette Janas, Karsten Schmidt, Masahiro Fukuoka, O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)91900-3
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149
Akira Inoue, Yasuo Saijo, Makoto Maemondo, Kazunori Gomi, Yutaka Tokue, Yuichiro Kimura, Masahito Ebina, Toshiaki Kikuchi, Takuya Moriya, Toshihiro Nukiwa, Severe acute interstitial pneumonia and gefitinib. The Lancet. ,vol. 361, pp. 137- 139 ,(2003) , 10.1016/S0140-6736(03)12190-3
Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller, Ronald B. Natale, Vincent Miller, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Ira Oliff, James A. Reeves, Michael K. Wolf, Annetta D. Krebs, Steven D. Averbuch, Judith S. Ochs, John Grous, Abderrahim Fandi, David H. Johnson, Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Journal of Clinical Oncology. ,vol. 22, pp. 785- 794 ,(2004) , 10.1200/JCO.2004.07.215
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Jantien Wanders, Richard S. Kaplan, Larry Rubinstein, Jaap Verweij, Martine Van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther, New Guidelines to Evaluate the Response to Treatment in Solid Tumors JNCI: Journal of the National Cancer Institute. ,vol. 92, pp. 205- 216 ,(2000) , 10.1093/JNCI/92.3.205